BiomX Inc. (PHGE-UN)
USD 0.9
(-5.26%)
USD 0.9
(-5.26%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 5.4 Million USD | -62.46% |
| 2022 | 14.38 Million USD | -25.05% |
| 2021 | 19.19 Million USD | 281.5% |
| 2020 | 5.03 Million USD | 487.85% |
| 2019 | 856 Thousand USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 8.84 Million USD | 0.0% |
| 2024 Q1 | 9.13 Million USD | -100.0% |
| 2023 FY | 5.4 Million USD | -62.46% |
| 2023 Q3 | 9.99 Million USD | -13.51% |
| 2023 Q1 | 12.89 Million USD | -10.4% |
| 2023 Q2 | 11.55 Million USD | -10.38% |
| 2023 Q4 | 5.4 Million USD | -45.95% |
| 2022 Q4 | 14.38 Million USD | -8.24% |
| 2022 FY | 14.38 Million USD | -25.05% |
| 2022 Q3 | 15.68 Million USD | -7.58% |
| 2022 Q2 | 16.96 Million USD | -9.1% |
| 2022 Q1 | 18.66 Million USD | -2.77% |
| 2021 Q1 | 4.73 Million USD | -5.84% |
| 2021 Q4 | 19.19 Million USD | 1.29% |
| 2021 Q3 | 18.95 Million USD | 288.46% |
| 2021 Q2 | 4.87 Million USD | 2.98% |
| 2021 FY | 19.19 Million USD | 281.5% |
| 2020 Q3 | 3.9 Million USD | 487.22% |
| 2020 Q1 | 740 Thousand USD | 0.0% |
| 2020 Q4 | 5.03 Million USD | 28.86% |
| 2020 FY | 5.03 Million USD | 487.85% |
| 2020 Q2 | 665 Thousand USD | -10.14% |
| 2019 Q4 | - USD | 0.0% |
| 2019 Q3 | - USD | -100.0% |
| 2019 Q2 | 500 Thousand USD | 0.0% |
| 2019 Q1 | 500 Thousand USD | 0.0% |
| 2019 FY | 856 Thousand USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2018 Q4 | 500 Thousand USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 495 Thousand USD | -991.313% |
| Ampio Pharmaceuticals, Inc. | - USD | -Infinity% |
| Armata Pharmaceuticals, Inc. | 82.3 Million USD | 93.437% |
| Actinium Pharmaceuticals, Inc. | 1.57 Million USD | -243.639% |
| Azitra, Inc. | 563.69 Thousand USD | -858.325% |
| Can-Fite BioPharma Ltd. | 13 Thousand USD | -41453.846% |
| Chromocell Therapeutics Corporation | - USD | -Infinity% |
| Calidi Biotherapeutics, Inc. | 2.06 Million USD | -162.233% |
| CEL-SCI Corporation | 11.6 Million USD | 53.441% |
| iBio, Inc. | 3.5 Million USD | -54.035% |
| Lineage Cell Therapeutics, Inc. | 2.07 Million USD | -160.966% |
| MAIA Biotechnology, Inc. | - USD | -Infinity% |
| Matinas BioPharma Holdings, Inc. | 2.89 Million USD | -86.598% |
| Navidea Biopharmaceuticals, Inc. | 1.87 Million USD | -188.612% |
| NovaBay Pharmaceuticals, Inc. | 1.1 Million USD | -387.545% |
| NanoViricides, Inc. | - USD | -Infinity% |
| Oragenics, Inc. | - USD | -Infinity% |
| BiomX Inc. | 5.4 Million USD | 0.0% |
| Protalix BioTherapeutics, Inc. | 4.62 Million USD | -16.901% |
| Palatin Technologies, Inc. | 163.78 Thousand USD | -3198.287% |
| Scorpius Holdings, Inc. | 12.61 Million USD | 57.172% |